Research Paper Volume 13, Issue 14 pp 18701—18717
Development and validation of a novel epigenetic-related prognostic signature and candidate drugs for patients with lung adenocarcinoma
Figure 9. Construction of a nomogram based on the epigenetic-related signature in the TCGA cohort. (A) The nomogram based on the signature in LUAD patients at 1, 3, and 5 years. (B–D) Calibration curves of nomogram for the signature at 1, 3, and 5 years.